A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinoma

Yan Song, Chunxia Du, Wen Zhang, Yongkun Sun, Lin Yang, Chengxu Cui, Yihebali Chi, Jianzhong Shou, Aiping Zhou, Jinwan Wang, Yan Sun

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Aim: Vascular endothelial growth facto receptor–tyrosine kinase inhibitors (VEGFR–TKIs) are widely used for metastatic renal cell carcinoma (mRCC). The aim of this study was to investigate the association between the response to VEGFR–TKIs and hyperlipidemia and hypothyroidism. Methods: Clinical data on 155 patients with mRCC treated with VEGFR-TKIs at the Cancer Hospital of Chinese Academy of Medical Sciences from 2006 to 2014 were retrospectively analyzed. All patients received first-line TKI therapy. Survival analysis was performed with a significance level of 0.05 using a Kaplan–Meier curve. The χ2 test was used for the intergroup comparison. The Cox regression model was used for the analysis of multiple factors affecting survival. Results: The median survival for the whole group (n = 155) was 36.2 months. A total of 57 patients (36.8 percent) developed hypothyroidism and 85 patients (54.9 percent) experienced hyperlipidemia. The response rate (RR) and median progression-free survival (mPFS) for patients with normal thyroid function were 32.7 percent and 9.1 months, respectively, 54.5 percent and 13.7 months with grade I hypothyroidism, 70.8 percent and 23.8 months with grade II hypothyroidism (P values of 0.001 and 0.017, respectively). The RR and mPFS for patients with normal blood lipids were 23.9 percent and 8.0 months, respectively, 54.0 percent and 12.9 months with grade I hyperlipidemia, 60.7 percent and 14.0 months with grade II hyperlipidemia, and 100.0 percent and 22.2 months with grade III hyperlipidemia. Significant differences in the RR and mPFS were seen between groups (the P values were 0.000 and 0.005, respectively). Conclusion: Hypothyroidism or hyperlipidemia may be effective predictive factors for response to treatment with VEGFR–TKIs in mRCC patients. Large-sample studies are warranted to further prove these results.

Original languageEnglish
Pages (from-to)174-180
Number of pages7
JournalAsia-Pacific Journal of Clinical Oncology
Issue number2
StatePublished - Jun 1 2016


  • hyperlipidemia
  • hypothyroidism
  • renal cell carcinoma
  • tyrosine kinase inhibitor


Dive into the research topics of 'A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this